This study investigates the use of lanreotide in patients with pancreatic cancer or pancreatic lesions that could become cancerous. The purpose of this study is to see if lanreotide can help prevent a complication called a pancreatic fistula after surgery.

The study evaluates the effectiveness of lanreotide in reducing the risk of pancreatic fistulas following surgery. It focuses on understanding how lanreotide may impact patient recovery and overall health outcomes.

• Who can participate: Adults 18 years and older with pancreatic cancer or pancreatic lesions, planning to undergo distal pancreatectomy, may be eligible. Participants must not have a history of malabsorption syndrome or have been treated with somatostatin analogues recently.
• Study details: Participants will receive either lanreotide or a placebo before surgery. Lanreotide is given as a shot under the skin. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.